ObsEva SA (NASDAQ:OBSV) announces the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).
The first paper, published in the Journal of Human Reproduction reports the results from a meta-analysis of three trials showing that nolasiban increased the likelihood of live birth following IVF. Key outcomes of the study were as follows:
A single 900 mg dose of nolasiban administered before fresh single embryo transfer increased live birth rates compared to placebo.
A patient-level combined analysis of the three studies showed a 5% absolute increase (15% relative increase) in ongoing pregnancy rate, with an odds ratio for nolasiban vs. placebo of 1.25 that was statistically significant (p=0.029).
The analyses also showed that the effect size for nolasiban was similar for ongoing pregnancy rate and live birth rate.
Nolasiban was well tolerated and there were few differences in maternal, obstetric and neonatal outcomes between the nolasiban and placebo treatment groups.
The second paper, published in Reproductive BioMedicine Online describes the results of a prospective mechanism of action study of nolasiban.
The study focused on nolasiban’s impact on uterine contractions, endometrial perfusion and endometrial mRNA expression. Key outcomes of the study were as follows:
Both doses of nolasiban (900 mg and 1,800 mg) showed trends of decreased contraction frequency and increased endometrial perfusion.
At 1800 mg, 10 endometrial genes were significantly differentially expressed, including three genes (DPP4, CXCL12 and IDO2) believed to be associated with decidualization and endometrial receptivity.
Nolasiban was well tolerated, supporting testing at higher doses in IVF patients.
Now read: Oragenics, EyeGate Pharmaceuticals leads healthcare gainers; Infinity Pharmaceuticals, NanoVibronix among major losers
Get alerts on
OBSV - ObsEva SA
Follow
4.93K Followers
Recommended For You
